TELO Telomir Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1971532 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY51.3%
TTM EPS YoY-159.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.3%
ROA-91.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.1%
Debt / equity0.00x
Current ratio19.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.44M | $2.24M |
| SG&A expense | $8.10M | $9.64M |
| Interest expense | — | $4.34M |
| Net income | -$10.41M | -$16.53M |
| EPS (basic) | -0.33 | -0.56 |
| EPS (diluted) | -0.33 | -0.56 |
| Weighted avg. shares (diluted) | 31.65M | 29.54M |
| Balance sheet | ||
| Cash & equivalents | $7.29M | $1.27M |
| Current assets | $7.34M | $1.32M |
| Total assets | $7.34M | $1.32M |
| Current liabilities | $1.43M | $680,968 |
| Total liabilities | $1.43M | $680,968 |
| Shareholders' equity | $5.91M | $643,037 |
| Shares outstanding | 34.38M | 29.76M |
| Cash flow statement | ||
| Operating cash flow | -$3.69M | -$5.07M |
| Financing cash flow | $9.71M | $6.34M |
| Stock-based compensation | $5.29M | $6.87M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.